(trade name)


Therapeutic: temporary class
Pharmacologic: adrenergics


Treatment of orthostatic dizziness, lightheadedness or feeling of impending blackout associated with symptomatic neurogenic orthostatic hypotension due to primary autonomic failure (Parkinson's disease, multiple system atrophy), dopamine beta-hydroxylase deficiency or non-diabetic autonomic neuropathy.


Acts as a synthetic precursor that is converted by dopa decarboxylase to norepinephrine which produces peripheral arterial and venous vasocontriction. Result is increased blood pressure.

Therapeutic effects

Increased blood pressure with decreased symptoms of orthostatic dizziness.


Absorption: Systemic absorption follows oral administration.
Distribution: Crosses the blood-brain barrier.
Metabolism and Excretion: Metabolized via catecholamine pathway; metabolites other than norepinephrine do not contribute to activity. 75% excreted by kidneys as parent drug and metabolites.
Half-life: 2.5 hr.

Time/action profile (↑ blood pressure)

POunknown1–4 hrunknown


Contraindicated in: Hypersensitivity to droxidopa or tartrazine (FD+C No. 5 [cross sensitivity between aspirin and FD+C No. 5 may occur); CCr <30 mL/min; Lactation: Discontinue droxidopa or discontinue breastfeeding.
Use Cautiously in: Hypertension (should be controlled prior to treatment); Mild to moderate renal impairment (↑ risk of adverse reactions); History of cardiovascular disease (may exacerbate hypertension, ischemic heart disease, arrhythmias or CHF); Geriatric: Elderly patients may be more sensitive to drug effects; Obstetric: Safe use during pregnancy has not been established; Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • confusion
  • dizziness
  • fatigue
  • headache


  • arrhythmias (life-threatening)
  • CHF (life-threatening)
  • myocardial ischemia (life-threatening)
  • supine hypertension


  • nausea


  • hyperpyrexia


Drug-Drug interaction

↑ risk of supine hypertension with other agents that ↑ blood pressure including ephedrine, norepinephrine, midodrine, pseudoephedrine, and triptans.Concurrent use of DOPA decarboxylase inhibitors may require dose adjustments.


Oral (Adults) 100 mg three times daily, may be ↑ by 100 mg three times daily up to 600 mg three times daily (last dose should be given at least 3 hr prior to bedtime).


Capsules (contain tartrazine): 100 mg, 200 mg, 300 mg

Nursing implications

Nursing assessment

  • Monitor blood pressure prior to and during therapy; more frequently during dose increases. Measure blood pressure in supine position and while head of bed is elevated; lessens risks of supine hypertension. If supine hypertension cannot be managed by elevating head of bed, reduce or discontinue droxidopa. Poorly managed supine hypertension may increase risk for cardiovascular events.
  • Monitor for symptom complex resembling neuroleptic malignant syndrome (fever, muscle rigidity, involuntary movements, altered consciousness, mental status changes) when dose is changed or when concomitant levodopa is abruptly reduced or discontinued, especially if patient is receiving neuroleptics. Syndrome is rare but potentially fatal.

Potential Nursing Diagnoses

Deficient knowledge, related to disease process and medication regimen (Patient/Family Teaching)


  • Oral: Administer upon arising in the morning, midday, and in late afternoon at least 3 hr prior to bedtime to reduce risk of supine hypertension during sleep. Swallow capsule whole; do not open, crush or chew.
    • May be administered without regard to food, but should be consistent each dose.

Patient/Family Teaching

  • Instruct patient to take droxidopa as directed. If dose is missed, omit and take next dose at scheduled time; do not double doses.
  • Advise patient to raise head of bed when resting or sleeping.
  • Instruct patient how to take blood pressure and manage elevations.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Increased blood pressure with decreased symptoms of orthostatic dizziness.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
The orthostatic hypotension drugs market analysis considers sale from midodrine, northera (droxidopa), fludrocortisone, and other drugs.
Neurogenic orthostatic hypotension in parkinson's disease: Evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag 2014;10:169-76.
Pharmacologic strategies aim to expand intravascular volume (fludrocortisone) or increase peripheral vascular resistance with the pressor agents midodrine or droxidopa. (17) Because of the prevalence of supine hypertension among patients with OH (up to 50%), slow titration and frequent monitoring is advised.
She was treated with droxidopa and then discharged once normothermic and stable [4] Chronic with acute episodes Spontaneous (6) improvement and discharge with a T of 35.2 [degrees]C Passive rewarming.
Droxidopa (Northern[R]) received FDA approval in 2014 for orthostatic hypotension in Parkinson's disease, MSA, and RAF (Brooks, 2014).
Droxidopa (Northern) is given orally and is indicated for symptomatic neurogenic orthostatic hypotension.
Droxidopa (Northera) is given orally and is indicated for symptomatic neurogenic orthostatic hypotension.
M2 EQUITYBITES-September 4, 2014-US subsidiary of Lundbeck launches Northera (droxidopa) capsules in US
M2 PHARMA-September 4, 2014-US subsidiary of Lundbeck launches Northera (droxidopa) capsules in US
Hauser found that PD patients who took the experimental drug droxidopa were able to reduce symptoms such as lightheadedness and dizziness, which can often affect PD patients with high blood pressure, when they stand up after being seated for a long time.
While we believe that higher doses of CH-4051 could provide enhanced therapeutic benefit in RA and that CH-4051 could be developed for other anti-inflammatory and autoimmune indications, we believe our current resources would be better allocated toward the planned completion of our Northera(TM) (droxidopa) development program in neurogenic orthostatic hypotension.